ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales

Key Takeaways Alnylam posted Q3 earnings of $2.90 per share, topping estimates on strong Amvuttra growth.Total revenues jumped 149% year over year to $1.25B, led by rising demand for Amvuttra.A $300M Roche milestone boosted collaboration revenues, lifting Alnylam's overall performance.Alnylam Pharmaceuticals (ALNY) reported third-quarter 2025 earnings of $2.90 per share, beating the Zacks Consensus Estimate of $1.67. The improvement was due to higher revenues from the sale of its lead drug, Amvuttra (vutris ...